{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T23:20:56Z","timestamp":1774048856092,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1124\/jpet.112.200030","type":"journal-article","created":{"date-parts":[[2012,11,29]],"date-time":"2012-11-29T05:30:56Z","timestamp":1354167056000},"page":"436-446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Inhibition of Toll-Like Receptor-Mediated Inflammation In Vitro and In Vivo by a Novel Benzoxaborole"],"prefix":"10.1016","volume":"344","author":[{"given":"Chen","family":"Dong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Sexton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Gertrudes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Akama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamra","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Virtucio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiao-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Bu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Jarnagin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne R.","family":"Freund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.112.200030_bib1","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.bmcl.2009.03.007","article-title":"Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis","volume":"19","author":"Akama","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/jpet.112.200030_bib2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1084\/jem.187.4.461","article-title":"Interleukin 6 is required for the development of collagen-induced arthritis","volume":"187","author":"Alonzi","year":"1998","journal-title":"J Exp Med"},{"key":"10.1124\/jpet.112.200030_bib3","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1039\/c0cs00131g","article-title":"Boron-containing inhibitors of synthetases","volume":"40","author":"Baker","year":"2011","journal-title":"Chem Soc Rev"},{"key":"10.1124\/jpet.112.200030_bib4","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1002\/1529-0131(200012)43:12<2648::AID-ANR4>3.0.CO;2-M","article-title":"Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis","volume":"43","author":"Bendele","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1124\/jpet.112.200030_bib5","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1517\/14712590802496928","article-title":"Biologics in asthma: difficulties and drawbacks","volume":"8","author":"Bousquet","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"10.1124\/jpet.112.200030_bib6","first-page":"958","article-title":"Toll-like receptor (TLR) 2 is upregulated on peripheral blood monocytes of patients with psoriatic arthritis: a role for a gram-positive inflammatory trigger?","volume":"29","author":"Carrasco","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1124\/jpet.112.200030_bib7","doi-asserted-by":"crossref","first-page":"27069","DOI":"10.1074\/jbc.M110.203398","article-title":"The rate of interleukin-1beta secretion in different myeloid cells varies with the extent of redox response to Toll-like receptor triggering","volume":"286","author":"Carta","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.112.200030_bib8","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10141","article-title":"Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial","volume":"46","author":"Cohen","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1124\/jpet.112.200030_bib9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.0022-202X.2005.23831.x","article-title":"Topical application of a novel immunomodulatory peptide, RDP58, reduces skin inflammation in the phorbol ester-induced dermatitis model","volume":"125","author":"De Vry","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1124\/jpet.112.200030_bib10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","article-title":"Immunological and inflammatory functions of the interleukin-1 family","volume":"27","author":"Dinarello","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1124\/jpet.112.200030_bib11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1084\/jem.170.1.321","article-title":"Genetic analysis of the human tumor necrosis factor alpha\/cachectin promoter region in a macrophage cell line","volume":"170","author":"Economou","year":"1989","journal-title":"J Exp Med"},{"key":"10.1124\/jpet.112.200030_bib12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1476-5381.1971.tb08071.x","article-title":"Inhibition of contact sensitivity in the mouse by topical application of corticosteroids","volume":"43","author":"Evans","year":"1971","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.112.200030_bib13","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/nprot.2007.258","article-title":"In vitro generation of CD4+ CD25+ regulatory cells from murine naive T cells","volume":"2","author":"Fantini","year":"2007","journal-title":"Nat Protoc"},{"key":"10.1124\/jpet.112.200030_bib14","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","article-title":"Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050","volume":"184","author":"Fridman","year":"2010","journal-title":"J Immunol"},{"key":"10.1124\/jpet.112.200030_bib15","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nrd2829","article-title":"Targeting innate immunity protein kinase signalling in inflammation","volume":"8","author":"Gaestel","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.112.200030_bib16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0022-3565(24)35089-X","article-title":"Pharmacokinetic-pharmacodynamic modeling of the immunomodulating agent susalimod and experimentally induced tumor necrosis factor-alpha levels in the mouse","volume":"291","author":"Gozzi","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.112.200030_bib17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1084\/jem.171.2.465","article-title":"Endotoxin-responsive sequences control cachectin\/tumor necrosis factor biosynthesis at the translational level","volume":"171","author":"Han","year":"1990","journal-title":"J Exp Med"},{"key":"10.1124\/jpet.112.200030_bib18","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/ni1274","article-title":"Limiting inflammatory responses during activation of innate immunity","volume":"6","author":"Han","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1124\/jpet.112.200030_bib19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrd3203","article-title":"Targeting Toll-like receptors: emerging therapeutics?","volume":"9","author":"Hennessy","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.112.200030_bib20","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11926-009-0051-z","article-title":"The role of toll-like receptors in rheumatoid arthritis","volume":"11","author":"Huang","year":"2009","journal-title":"Curr Rheumatol Rep"},{"key":"10.1124\/jpet.112.200030_bib21","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.cell.2007.09.008","article-title":"Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide","volume":"130","author":"Jin","year":"2007","journal-title":"Cell"},{"key":"10.1124\/jpet.112.200030_bib22","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.immuni.2008.07.007","article-title":"Structures of the toll-like receptor family and its ligand complexes","volume":"29","author":"Jin","year":"2008","journal-title":"Immunity"},{"key":"10.1124\/jpet.112.200030_bib23","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.4049\/jimmunol.163.9.5049","article-title":"IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation","volume":"163","author":"Joosten","year":"1999","journal-title":"J Immunol"},{"key":"10.1124\/jpet.112.200030_bib24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1124\/jpet.112.200030_bib25","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.cell.2007.08.002","article-title":"Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran","volume":"130","author":"Kim","year":"2007","journal-title":"Cell"},{"key":"10.1124\/jpet.112.200030_bib26","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrd2805","article-title":"Averting inflammation by targeting the cytokine environment","volume":"9","author":"Kopf","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"Spec No","key":"10.1124\/jpet.112.200030_bib27","doi-asserted-by":"crossref","first-page":"C169","DOI":"10.1007\/BF01972756","article-title":"Anti-inflammatory properties of the protein kinase C inhibitor, 3-[1-[3-(dimethylamino)propyl]-1H-indol-3-yl]-4-(1H-indol-3-yl)-1H- pyrrole-2,5-dione monohydrochloride (GF109203X) in the PMA-mouse ear edema model","volume":"39","author":"Kuchera","year":"1993","journal-title":"Agents Actions"},{"key":"10.1124\/jpet.112.200030_bib28","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1128\/MCB.19.6.4311","article-title":"Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA","volume":"19","author":"Lai","year":"1999","journal-title":"Mol Cell Biol"},{"key":"10.1124\/jpet.112.200030_bib29","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/1871526510808030144","article-title":"Toll-like receptors in skin infections and inflammatory diseases","volume":"8","author":"Lai","year":"2008","journal-title":"Infect Disord Drug Targets"},{"key":"10.1124\/jpet.112.200030_bib30","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1096\/fasebj.8.13.7926375","article-title":"Interleukin-1 alpha mediates phorbol ester-induced inflammation and epidermal hyperplasia","volume":"8","author":"Lee","year":"1994","journal-title":"FASEB J"},{"key":"10.1124\/jpet.112.200030_bib31","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.112.200030_bib32","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1016\/j.bmcl.2010.04.129","article-title":"Synthesis and evaluation of novel alpha-amino cyclic boronates as inhibitors of HCV NS3 protease","volume":"20","author":"Li","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/jpet.112.200030_bib33","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.rdc.2010.02.005","article-title":"A multitude of kinases\u2014which are the best targets in treating rheumatoid arthritis?","volume":"36","author":"Lindstrom","year":"2010","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1124\/jpet.112.200030_bib34","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1126\/science.1155406","article-title":"Structural basis of toll-like receptor 3 signaling with double-stranded RNA","volume":"320","author":"Liu","year":"2008","journal-title":"Science"},{"key":"10.1124\/jpet.112.200030_bib35","doi-asserted-by":"crossref","first-page":"674363","DOI":"10.1155\/2010\/674363","article-title":"Targeting TLR\/IL-1R signalling in human diseases","volume":"2010","author":"Loiarro","year":"2010","journal-title":"Mediators Inflamm"},{"key":"10.1124\/jpet.112.200030_bib36","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1517\/17460441.3.6.607","article-title":"The challenge of selecting protein kinase assays for lead discovery optimization","volume":"3","author":"Ma","year":"2008","journal-title":"Expert Opin Drug Discov"},{"key":"10.1124\/jpet.112.200030_bib37","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1189\/jlb.71.6.1026","article-title":"Post-transcriptional regulation of TNF-alpha during in vitro differentiation of human monocytes\/macrophages in primary culture","volume":"71","author":"MacKenzie","year":"2002","journal-title":"J Leukoc Biol"},{"key":"10.1124\/jpet.112.200030_bib38","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nri1957","article-title":"Toll-like receptors in systemic autoimmune disease","volume":"6","author":"Marshak-Rothstein","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1124\/jpet.112.200030_bib39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.yadr.2008.09.004","article-title":"Toll-like receptors in skin","volume":"24","author":"Miller","year":"2008","journal-title":"Adv Dermatol"},{"key":"10.1124\/jpet.112.200030_bib40","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood-2008-03-146720","article-title":"Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages","volume":"113","author":"Netea","year":"2009","journal-title":"Blood"},{"key":"10.1124\/jpet.112.200030_bib41","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1471-4892(03)00080-8","article-title":"Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases","volume":"3","author":"O\u2019Neill","year":"2003","journal-title":"Curr Opin Pharmacol"},{"key":"10.1124\/jpet.112.200030_bib42","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/nature07830","article-title":"The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex","volume":"458","author":"Park","year":"2009","journal-title":"Nature"},{"key":"10.1124\/jpet.112.200030_bib43","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/672395","article-title":"DAMPening inflammation by modulating TLR signalling","author":"Piccinini","year":"2010","journal-title":"Mediators Inflamm"},{"key":"10.1124\/jpet.112.200030_bib44","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1126\/science.282.5396.2085","article-title":"Defective LPS signaling in C3H\/HeJ and C57BL\/10ScCr mice: mutations in Tlr4 gene","volume":"282","author":"Poltorak","year":"1998","journal-title":"Science"},{"key":"10.1124\/jpet.112.200030_bib45","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1126\/science.1142189","article-title":"An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site","volume":"316","author":"Rock","year":"2007","journal-title":"Science"},{"key":"10.1124\/jpet.112.200030_bib46","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1155\/S0962935193000754","article-title":"LPS-induced serum TNF production and lethality in mice: effect of L-carnitine and some acyl-derivatives","volume":"2","author":"Ruggiero","year":"1993","journal-title":"Mediators Inflamm"},{"key":"10.1124\/jpet.112.200030_bib47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/00002018-200629010-00004","article-title":"Fulfilling an unmet need in psoriasis : do biologicals hold the key to improved tolerability?","volume":"29","author":"Shear","year":"2006","journal-title":"Drug Saf"},{"key":"10.1124\/jpet.112.200030_bib48","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1096\/fasebj.2.14.3053308","article-title":"Collagen autoimmunity and arthritis","volume":"2","author":"Stuart","year":"1988","journal-title":"FASEB J"},{"issue":"Suppl 1","key":"10.1124\/jpet.112.200030_bib49","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1478-6354-13-S1-S5","article-title":"Advances in rheumatology: new targeted therapeutics","volume":"13","author":"Tak","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1124\/jpet.112.200030_bib50","doi-asserted-by":"crossref","first-page":"6975","DOI":"10.4049\/jimmunol.167.12.6975","article-title":"Bacterial peptidoglycan-induced tnf-alpha transcription is mediated through the transcription factors Egr-1, Elk-1, and NF-kappaB","volume":"167","author":"Xu","year":"2001","journal-title":"J Immunol"},{"key":"10.1124\/jpet.112.200030_bib51","doi-asserted-by":"crossref","first-page":"17795","DOI":"10.1074\/jbc.272.28.17795","article-title":"Lipopolysaccharide induction of the tumor necrosis factor-alpha promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-kappaB transcription factors","volume":"272","author":"Yao","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.112.200030_bib52","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1126\/science.1215584","article-title":"Structural basis of TLR5-flagellin recognition and signaling","volume":"335","author":"Yoon","year":"2012","journal-title":"Science"},{"key":"10.1124\/jpet.112.200030_bib53","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.4049\/jimmunol.179.3.1872","article-title":"Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection","volume":"179","author":"Zalevsky","year":"2007","journal-title":"J Immunol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524185096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524185096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.112.200030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T17:18:41Z","timestamp":1739985521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524185096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0022356524185096"],"URL":"https:\/\/doi.org\/10.1124\/jpet.112.200030","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of Toll-Like Receptor-Mediated Inflammation In Vitro and In Vivo by a Novel Benzoxaborole","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.112.200030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2013 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}